Status:
COMPLETED
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Human Genome Sciences Inc.
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
Eligibility Criteria
Inclusion
- Primary
- Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or recurrent NSCLC
- Previously treated and failed to respond to standard therapy or progressed after standard therapy
- 18 years of age or older
- Primary
Exclusion
- Received a non-FDA approved investigational agent within the last 4 weeks.
- Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies
- Infection requiring antibiotics or hospitalization within the last 2 weeks
- HIV, Hepatitis-B, Hepatitis-C
- Pregnant or breast-feeding women
- Major surgery within the last 4 weeks
- History of other cancers within the past 5 years
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00092924
End Date
March 1 2005
Last Update
August 2 2013
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Cancer Center
Denver, Colorado, United States, 80220
2
Rush Medical College
Chicago, Illinois, United States, 60612
3
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
4
Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203